Intrathecal pemetrexed improves survival outcomes in previously treated EGFR-mutant advanced non-small-cell lung cancer with leptomeningeal metastases
IP represents a potentially viable treatment option for managing LM in patients with EGFR-TKI-resistant <i>EGFR</i>-mutant advanced NSCLC. Clinical responses as measured by the improvement of neurological symptoms/signs and KPS scores were associated with favorable survival outcomes.
Authors
- Xiaoquan Chen
- Xingxiang Pu (ORCID: https://orcid.org/0000-0002-2743-7080)
- Haoyue Qin
- Huan Yan (ORCID: https://orcid.org/0000-0001-7966-0359)
- Lin Zhang (ORCID: https://orcid.org/0000-0003-1961-7812)
- Xing Zhang (ORCID: https://orcid.org/0000-0001-8542-8353)
- Liang Zeng (ORCID: https://orcid.org/0000-0003-3033-5613)
- Zhiguo Zhou (ORCID: https://orcid.org/0000-0001-9570-6986)
- Yongchang Zhang (ORCID: https://orcid.org/0000-0002-6829-7176)
- Zhe Huang (ORCID: https://orcid.org/0000-0002-9201-9491)
- Liqun Li (ORCID: https://orcid.org/0000-0001-7839-1118)
- Wenjuan Jiang (ORCID: https://orcid.org/0009-0006-4068-8892)
- Yuda Zhang
- Zhan Wang (ORCID: https://orcid.org/0009-0000-6968-7638)
- Yangqian Chen
- Fanxu Zeng
- Hongzhi Ma
- Nong Yang
Institutions
- Central South University (CN)
- Hunan Cancer Hospital (CN)
Publication Details
- Journal
- Heliyon
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.heliyon.2024.e40703
- Citations
- 3
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.26
Funders
- National Natural Science Foundation of China